BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29055700)

  • 41. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
    Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
    ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using anti-PD-L1 antibody conjugated gold nanoshelled poly (Lactic-co-glycolic acid) nanocapsules loaded with doxorubicin: A theranostic agent for ultrasound imaging and photothermal/chemo combination therapy of triple negative breast cancer.
    Jiang H; Zhou Y; Zheng D; Cheng Y; Xiang D; Jiang L; Du J
    J Biomed Mater Res A; 2024 Mar; 112(3):402-420. PubMed ID: 37941485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
    Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
    ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Self-Assembled Cationic Biodegradable Nanoparticles from pH-Responsive Amino-Acid-Based Poly(Ester Urea Urethane)s and Their Application As a Drug Delivery Vehicle.
    He M; Potuck A; Kohn JC; Fung K; Reinhart-King CA; Chu CC
    Biomacromolecules; 2016 Feb; 17(2):523-37. PubMed ID: 26650653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The application of aptamer 5TR1 in triple negative breast cancer target therapy.
    Luo S; Wang S; Luo N; Chen F; Hu C; Zhang K
    J Cell Biochem; 2018 Jan; 119(1):896-908. PubMed ID: 28671278
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and
    Darabi F; Saidijam M; Nouri F; Mahjub R; Soleimani M
    Biomed Res Int; 2022; 2022():6253978. PubMed ID: 35845934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
    Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
    Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody.
    Liu J; Wang P; Huang B; Cheng Q; Duan Y; Chen L; Ma T; Zhu C; Li D; Fan W; Yu M
    Int J Pharm; 2022 Aug; 624():121969. PubMed ID: 35803533
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
    He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
    ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
    Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
    Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.
    Niu M; Valdes S; Naguib YW; Hursting SD; Cui Z
    Mol Pharm; 2016 Jun; 13(6):1833-42. PubMed ID: 27074028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Redox- and light-responsive alginate nanoparticles as effective drug carriers for combinational anticancer therapy.
    Zhang C; Shi G; Zhang J; Niu J; Huang P; Wang Z; Wang Y; Wang W; Li C; Kong D
    Nanoscale; 2017 Mar; 9(9):3304-3314. PubMed ID: 28225139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
    Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
    J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doxorubicin-loaded dextran-based nano-carriers for highly efficient inhibition of lymphoma cell growth and synchronous reduction of cardiac toxicity.
    Fang Y; Wang H; Dou HJ; Fan X; Fei XC; Wang L; Cheng S; Janin A; Wang L; Zhao WL
    Int J Nanomedicine; 2018; 13():5673-5683. PubMed ID: 30288040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mesoporous silica nanoparticles combining Au particles as glutathione and pH dual-sensitive nanocarriers for doxorubicin.
    Xu S; Li Y; Chen Z; Hou C; Chen T; Xu Z; Zhang X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():258-264. PubMed ID: 26652372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polyethylene glycol-conjugated chondroitin sulfate A derivative nanoparticles for tumor-targeted delivery of anticancer drugs.
    Lee JY; Park JH; Lee JJ; Lee SY; Chung SJ; Cho HJ; Kim DD
    Carbohydr Polym; 2016 Oct; 151():68-77. PubMed ID: 27474544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interconnected hyaluronic acid derivative-based nanoparticles for anticancer drug delivery.
    Park JH; Cho HJ; Termsarasab U; Lee JY; Ko SH; Shim JS; Yoon IS; Kim DD
    Colloids Surf B Biointerfaces; 2014 Sep; 121():380-7. PubMed ID: 24993066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
    Zeng X; Morgenstern R; Nyström AM
    Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.